Suven Life Sciences today said it has been granted a product patent by New Zealand and the US, each corresponding to a new chemical entity (NCE) for treatment of disorders associated with neuro-degenerative diseases. These patents are valid through 2034, the company said in a BSE filing.

“We are pleased by the grant of these patents to Suven for our pipeline of molecules in the CNS arena, which are being developed for cognitive disorders with high unmet medical need, with a huge market potential globally,” Suven Life CEO Venkat Jasti said.

The granted claims of patents are being developed as therapeutic agents useful in the treatment of cognitive impairment associated with neuro-degenerative disorders such as Alzheimer’s disease, attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson’s and schizophrenia and sleep disorders such as Narcolepsy, it added. Suven Life Sciences shares were trading 2.13 per cent down at Rs 192.60 on BSE.